Geron Corp (GERN) stock
Close on Nov 12, 2026Market cap $638.62MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $638.62M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.82
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$47.83M
- EPS, diluted
- -$0.07
- Book value per share
- $0.34
- Diluted shares
- 674M
Trading
- Next earnings
- Feb 24, 2027 (estimated, before the open)
- Previous close
- $1.02
- Open
- $1.00
- Day's range
- $0.96 – $1.02
- Volume
- 10,354,730
- Average volume (20 days)
- 18,229,716
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.07
- 52-week range
- $0.84 – $2.01
- RSI (14 days)
- 42.3
- Volatility (1 year)
- 67.6%
- Relative volume
- 0.89×
- WACC
- 10.5%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | GERN | S&P 500 | Difference | GERN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.5% | -2.7% | −15.8 pts | ||
| 3 months | -36.7% | -1.7% | −34.9 pts | ||
| Year to date | -24.7% | +11.9% | −36.6 pts | ||
| 1 year | -19.8% | +12.0% | −31.8 pts | ||
| 3 years | -42.9% | +78.2% | −121.1 pts | -17.0% | +21.2% |
| 5 years | -36.7% | +73.2% | −109.9 pts | -8.7% | +11.6% |
| 10 years | -54.8% | +309.6% | −364.5 pts | -7.6% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Geron filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Update
- Update
About Geron
Pharmaceutical Preparations
Geron Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutics for hematologic malignancies. Its primary product is RYTELO (imetelstat), an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. In addition to commercializing RYTELO, the company conducts clinical research and development, including advanced clinical trials such as the IMpactMF Phase 3 study evaluating imetelstat in patients with relapsed or refractory myelofibrosis. Geron's operations serve eligible patients, healthcare providers, and clinical trial participants across specialized oncology care.
Company profile, executives and historyGeron stock: common questions
What is Geron's stock price?
GERN closed at $0.99 on Nov 12, 2026, down 2.55% on the day. Over the past 52 weeks it traded between $0.84 and $2.01.
What is Geron's market cap?
Geron was worth $638.62M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is GERN's P/E ratio?
Geron lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.07), so it has no meaningful P/E ratio.
Does Geron pay a dividend?
No. Geron has not paid a cash dividend over the last twelve months.
When does Geron report earnings next?
Geron is expected to report Q4 FY2026 results on Feb 24, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has GERN stock performed over the past year?
Including dividends, GERN returned -19.8% over the past year, against +12.0% for the S&P 500.
How many GERN shares are sold short?
67M shares were sold short at the latest FINRA report, 10.44% of the float, or 3.9 days of average trading volume.
Who are Geron's competitors?
Companies most similar to Geron by business, industry and size include OTLC, OMER, SNDX, DMRA, RIGL.
See a number that looks wrong?